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Nearly a century ago, German scientist Otto Warburg 
observed that solid tumors deviate from most normal tissues in 
their ravenous consumption of glucose and high rates of aerobic 
glycolysis.[1]  This dysfunctional metabolism has been proposed to 
convey a survival advantage to tumor cells, allowing them to 
proliferate in normoxic or hypoxic environments and to evade 
killing by the immune system.[2] The molecular mechanisms 
underlying the Warburg effect have been elucidated, most notably 
tumor cells’ overexpression of the glucose transporter GLUT-1[3] 
and the enzymes of glycolysis, including lactate dehydrogenase 
isoform A (LDH-A).[4] Targeting dysregulated tumor cell 
metabolism is emerging as a tantalizing anticancer strategy.[2a]  
Herein we report the first demonstration of dually targeting the 
Warburg effect using a glucose-conjugated LDH-A inhibitor, thus 
exploiting both the preferential glucose uptake and increased 
glycolysis of cancer cells (Figure 1a).   
A common clinical application of the selective uptake of 
glucose into cancerous versus normal tissues is the use of the 
radiolabeled glucose analog 2-deoxy-2-(18F)fluoro-D-glucose 
(18F-FDG).  18F-FDG is a ubiquitous imaging tool for diagnosing 
and staging many types of cancers, including lung, breast, 
endometrial and colorectal carcinomas, several types of sarcomas, 
and both Hodgkin’s and non-Hodgkin’s lymphomas.[5] In addition, 
the conjugation of glucose[6] or similar sugars potentially 
recognized by GLUT-1 receptors[7] to anticancer agents offers 
potential selective targeting of cytotoxic drugs,[8] with the most 
clinically advanced glycoconjugate, glufosfamide, reaching phase 
II and III clinical trials in Europe and the United States.[9] 
 
Figure 1. (a) Dual-targeting of the Warburg effect by a glucose-
conjugated LDH-A inhibitor.  (b) Structures and in vitro Ki values vs. 
NADH in LDH-A of unconjugated and glucose-conjugated N-
hydroxyindole (NHI) class compounds. Values are reported as the mean 
± SD of three or more independent experiments. 
LDH-A is a key enzyme in glycolysis, catalyzing the 
reduction of pyruvate to lactate (Figure 1a), generating NAD+ and 
thus enabling continued glycolysis and ATP production even in 
the absence of aerobic oxidation of NADH.[10] Much of the lactate 
produced in this reaction is excreted into the tumor 
microenvironment, acidifying it to limit immune access to tumor 
tissue.[11]  Overexpression of LDH-A has been noted in numerous 
solid tumors and has been found to correlate with poor clinical 
outcome in patients;[12] these data have been corroborated by a 
number of studies demonstrating that cancer cells in which LDH-
A activity has been attenuated (through RNA interference) are 
less viable and less tumorigenic.[13] Importantly, LDH-A 
inhibition is unlikely to harm normal tissues: LDH-A deficiency is 
present in the human population at a frequency of 0.0012,[14] and 
those individuals heterozygous for LDH-A deficiency have no 
clinical presentation, while homozygotes present with 
myoglobinuria only upon extreme exertion.[15]  
We recently reported the discovery of N-hydroxyindole 
(NHI)-based LDH-A inhibitors (exemplified by compound NHI-1, 
Figure 1b) as anticancer agents.[16] While other classes of in vitro 
LDH-A inhibitors exist,[17] including the natural product gossypol, 
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[18] its derivative FX-11,[19] the pyruvate mimetic oxamate,[20] the 
gallic acid derivative galloflavin,[21] compounds developed in a 
fragment-based approach by AstraZeneca[22] and by ARIAD 
Pharmaceuticals,[23] and in screening by Genentech,[24] the NHI 
inhibitors are attractive candidates due to their facile syntheses, 
selective toxicity toward cancerous cells, and in vitro and cell 
culture efficacy.[16a]  Thus the NHIs are an outstanding compound 
class to demonstrate the concept of dually targeting the Warburg 
effect by linking glucose to a glycolytic enzyme inhibitor. 
We previously reported compound NHI-1 (Figure 1b) as a 
competitive inhibitor of LDH-A in vitro, with the ability to inhibit 
the conversion of 13C glucose to 13C lactate in HeLa human 
cervical carcinoma cells when used at a high concentration (500 
µM).[16a]  Later, methyl ester NHI-2 was found to inhibit LDH-A 
in vitro and kill cancer cells in culture.[16b]  Further, NHI-2 proved 
to be stable after uptake by cancer cells, suggesting its improved 
anti-proliferative activity is due improved cell uptake compared to 
NHI-1.[16b] In efforts to enhance the tumor cell selectivity and 
efficacy of NHI-1 and NHI-2, their glucose conjugates NHI-Glc-
1 and NHI-Glc-2 (Figure 1b) were synthesized and evaluated (see 
supporting information for synthetic routes).  
Evaluation versus LDH-A in vitro revealed that non-
conjugated (NHI-1 and NHI-2)[16b] and glucose-conjugated 
derivatives (NHI-Glc-1 and NHI-Glc-2) are competitive 
inhibitors of the NADH binding pocket of LDH-A, with 
conjugation to the sugar moiety of the NHI derivatives lowering 
the inhibitory potency of the resulting conjugates by 2- (NHI-Glc-
1) and 7-fold (NHI-Glc-2) (Figure 1b).  To rule out inhibition by 
aggregation, additional assays were conducted in the presence of 
Triton X detergent and bovine serum albumin (BSA) using 
conditions described previously.[25]  The NHI series, as 
exemplified by NHI-1, NHI-2, and NHI-Glc-2, retained its 
inhibitory potency against LDH-A in the presence of both Triton 
X and BSA (Figure S1). 
 
 
Figure 2. Binding pose resulting from MD simulation of the LDH-A 
complex with compound NHI-Glc-2. (a) disposition of the ligand into the 
enzyme active site displaying the protein backbone; (b) skewed view of 
the complex showing the protein residues that are most relevant for 
interaction with the inhibitor. 
Docking studies followed by molecular dynamic (MD) 
simulations were carried out to examine the interaction of the 
glucose conjugates with LDH-A. Starting from the average 
structure of the minimized LDH-A/NHI-1 complex that we 
recently reported,[16a] compound NHI-Glc-2 was docked in the 
protein by using GOLD 5.1,[21] and the minimized complex was 
then subjected to 10 ns of MD simulation using Amber 11.[22] As 
shown in Figure 2, the ester of NHI-Glc-2 forms a H-bond with 
R169, similar to that found by MD simulation of ester-aglycone 
NHI-2.[16b] The indole portion is located in a pocket defined by 
N138, H193, G194, A238, and Y239, with its 6-phenyl 
substituent protruding toward the enzyme cavity entrance channel. 
The glucose moiety establishes strong interactions in the NADH-
binding pocket; in particular, H-bonds with Asn138 and with the 
backbone of Val136 and Ser137 (Figure 2b and Table S1). These 
additional interactions largely compensate for the loss of those 
involving the N-OH group of non-conjugated derivatives 
Interestingly, both Val136 and Asn138 were previously found to 
be similarly involved in crucial interactions with the enzyme 
cofactor in the X-ray structure of the complex of LDH-A with 
NADH and oxamate (1I10 PDB code).[23]  
Evaluation of these compounds versus a panel of cancer cell 
lines representing the types of cancers in which LDH-A is 
commonly shown to be overexpressed[12b, 26] and which highly 
express GLUT-1[27] demonstrate that, while NHI-Glc-1 is inactive 
(IC50 > 200 µM in HeLa cells), NHI-Glc-2 has 3-5-fold and 6-9-
fold enhanced potencies, compared to NHI-2 and NHI-1, 
respectively (Table 1).  All compounds are significantly less 
potent against non-cancerous mouse embryonic fibroblasts (WT-
MEF, Table 1). 
Table 1. Cancer cell toxicity of NHI class LDH-A inhibitors [a] 
Cancer 
cell line 
Tissue of 
origin 
IC50 values (µM) 
NHI-1 NHI-2 NHI-Glc-2 
HeLa Cervix 43.8 ± 4.6 [16b] 33.4 ± 1.0[16b] 7.2 ± 0.2 
A549 Lung 131.0 ± 17.6 44.1 ± 6.2 17.2 ± 3.0 
H1299 Lung 141.0 ± 11.1 61.1 ± 11.8 18.0 ± 1.5 
H226 Lung 120.7 ± 7.8 43.4 ± 5.3 16.8 ± 2.8 
MCF-7 Breast 124.3 ± 7.1 64.9 ± 13.1 16.7 ± 1.1 
BT549 Breast 110.1 ± 9.5 34.5 ± 10.0 12.7 ± 0.4 
IGROV-1 Ovary 123.3 ± 6.8 57.4 ± 7.3 15.5 ± 3.0 
WT-MEF 
Normal 
fibroblast 
245.0 ± 13.0 80.5 ± 8.2 32.2 ± 0.2 
 
[a] All cells were seeded at 5000 cells/well in plates in which vehicle or 
compound in DMSO was pre-dispensed (1% final concentration DMSO 
in all wells).  Following a 72 hour incubation, biomass was quantified 
using the Sulforhodamine B (SRB) assay, and IC50 values (in µM) were 
calculated from logistical dose response curves.  Averages were 
obtained from three independent experiments, and error is standard 
error (n=3). 
To assess efficacy in inhibiting lactate production in cells, 
HeLa cells were treated with varying concentrations of NHIs and 
other reported LDH-A inhibitors including FX-11,[19a] 
galloflavin,[21] and the AstraZeneca compound AZ 33[22] 
(structures are depicted in Figure S2).  After 8 hours of treatment, 
the lactate present in cell culture media was quantified by GC-MS. 
This GC-MS based assay for lactate detection has several-fold 
increased sensitivity over the 13C NMR-based assay previously 
employed,[16a] allowing for precise detection of low micromolar 
lactate (versus the low millimolar detection limit afforded by 13C 
NMR).  As shown in Figure 3a, consistent with the proliferation 
assay results, NHI-Glc-1 has only modest effects at 200 µM, 
similar to its aglycone NHI-1 (which required 500 µM for 
substantial efficacy, as previously reported[16a]). On the contrary, 
treatment with NHI-Glc-2 leads to significant, dose-dependent 
reduction in cellular lactate production, and is more potent than its 
aglycone NHI-2. The hexokinase inhibitor 2-deoxyglucose also 
has a modest effect at very high concentrations (10 mM), whereas 
negligible effects are observed for LDH-A inhibitors FX-11, 
galloflavin, and AZ 33 (each tested at 100 µM). Cytotoxic 
compounds that do not impact glucose metabolism, such as the 
topoisomerase II inhibitor etoposide, have no effect on lactate 
production.  Furthermore, the reduction in lactate production 
observed with the NHIs precedes the onset of cell death (Figure 
S3). 
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Figure 3. (a) Treatment of HeLa cells with various compounds indicates that NHI-Glc-2 dose-dependently reduces lactate production, comparing favorably in 
this regard to NHI-2.   The effect of NHI-Glc-2 is significantly more potent than that of NHI-1, NHI-Glc-1, and other reported LDH-A inhibitors, FX-11, galloflavin, 
and AZ 33.  HeLa cells were treated for 8 hours with compound or DMSO vehicle (1% final concentration DMSO) in DMEM media.  To quantify the lactate 
produced by the cells, derivatized cell culture media was analyzed by GC-MS.  Lactate peaks were normalized using an internal standard present in each 
sample, and are presented as percent of vehicle lactate production.  Averages are shown, with error bars denoting standard error of three or more 
independent experiments.  (b) Compound NHI-Glc-2 is more readily taken up by cancer cells than NHI-1 or NHI-2.  A549 cells were treated with compound 
(100 µM) or vehicle (0.2% final concentration DMSO).  Cells were collected after 4 hours, washed twice in PBS, sonicated in methanol, and analyzed via LC-
MS.  UV trace integration areas, standardized by sample fresh weights, were converted to relative concentrations using calibration of known concentrations 
(Figure S4).  Relative concentrations are presented as ratios of the concentration of NHI-1.  Error is standard error of three or more independent experiments. 
To test if the enhanced cancer cell toxicity and lactate 
production inhibition by NHI-2 and NHI-Glc-2 was due to 
enhanced cell uptake, the ability of these compounds to penetrate 
A549 cells was evaluated. To compare the relative intracellular 
concentrations, A549 cells were treated with equimolar compounds 
or vehicle for 4 hours, and cell lysates were subjected to LC-MS 
analysis using calibrations of known concentrations generated using 
the same LC-MS protocol (Figure S4). In A549 cells, NHI-2 was 
present in approximately 4.5-fold higher concentrations in the 
lysate of samples compared to NHI-1, and NHI-Glc-2 was present 
at approximately 24-fold higher concentrations in the lysate 
samples (Figure 3b).  NHI-Glc-2 does not appear to be appreciably 
cleaved to NHI-2 or NHI-Glc-1 inside the cell (representative UV 
traces are shown in Figure S5).  
To examine whether NHI-Glc-2 is entering cells via GLUT 
transporters, a competition assay was performed between NHI-Glc-
2 and GB2-Cy3, a fluorescent Cy3-linked glucose bioprobe 
recently developed by Park and coworkers.[28]  While a number of 
glucose bioprobes are known,[29] GB2-Cy3 has been shown to 
possess an enhanced fluorescent signal in live cells and an 
enhanced ability to compete with glucose for uptake in cultured 
cells compared to the known 2-deoxyglucose analog 2-[N-(7-
nitrobenx-2-oxa-1,3-diazol-4-yl)-amino]-2-deoxy-D-glucose (2- 
 
Figure 4. A549 cells were grown in RPMI 1640 growth media on cover 
glass bottom dishes (60,000 cells/dish). When cells reached 70% 
confluence, they were treated with GB2-Cy3 (2.5 µM) in the absence (a) 
or the presence of NHI-2 (10 µM) (b), NHI-Glc-2 (10 µM) (c), or glucose 
(10 µM) (d) for 30 minutes at 37 °C. Cellular fluorescence was observed 
using a Zeiss LSM700 confocal microscope, using a photomultiplier gain 
of 844 and a laser power of 555 nm (representative images are shown).  
(e)  The intracellular fluorescence of NHI-Glc-2- and glucose-treated cells 
is statistically significantly less than that of vehicle-treated cells, indicating 
that the uptake of the fluorescent GB2-Cy3 probe in these cells was 
inhibited by treatment with NHI-Glc-2 and glucose.  The mean 
fluorescence intensities of each sample were calculated by averaging the 
fluorescence intensities of 40-60 cells per treatment over three 
independent experiments.  Error bars denote standard error (n=3); 
statistical analysis was performed using an unpaired, two-tailed Student’s 
t test. * denotes p<0.05; ** denotes p<0.01. 
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NBDG), with 5 µM GB2-Cy3 more potently inhibiting glucose 
uptake than 50 µM 2-NBDG.[30]  For our purposes, cellular 
fluorescence was used as a readout for whether the cellular uptake 
of GB2-Cy3 was hindered by co-incubation with compound.  A549 
cells, which highly express GLUT-1[27b], were treated for 30 
minutes with 2.5 µM GB2-Cy3 in the presence of either vehicle or 
10 µM NHI-2, NHI-Glc-2, or glucose.  Cells were then imaged by 
confocal laser scanning microscopy, and fluorescence was 
quantified and averaged over 40-60 cells per treatment.  Treatment 
with NHI-Glc-2 and glucose caused a statistically significant 
decrease in fluorescence compared to vehicle, whereas treatment 
with NHI-2 did not (Figure 4), thus suggesting that NHI-Glc-2 and 
glucose are competing with GB2-Cy3 for cellular entry through 
GLUT transporters.   To confirm that loss of cell viability was not 
skewing this result, 30 minute toxicity assays were performed for 
both NHI-2 and NHI-Glc-2; the results show that no appreciable 
loss of viability is observed at compound concentrations up to 200 
µM at 30 minute treatment times. 
In summary, NHI-Glc-2 has been designed as the first 
compound aimed at dual targeting of the Warburg effect, created to 
exploit a) the enhancement in glucose uptake, and b) the increased 
glycolysis that characterizes many aggressive tumors. NHI-Glc-2 
has improved potency against cancer cells and increased cell 
permeability compared to its aglycone, showing a modest reduction 
in its inhibition potency on isolated enzyme that is highly 
compensated by its improved cell uptake via GLUT transporters.  
This compound will be an outstanding tool to fully probe the 
tractability of LDH-A inhibition in advanced mammalian tumor 
models. In addition, these results suggest application of this dual 
targeting strategy to inhibitors of the various other enzymes 
involved in glycolysis. 
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Dual Targeting of the Warburg Effect 
with a Glucose-Conjugated Lactate 
Dehydrogenase Inhibitor 
Glucose transporters and the glycolysis enzyme lactate dehydrogenase A (LDH-A) 
are both overexpressed in cancer cells, two proliferation tactics that underlie the 
phenomenon known as the Warburg effect.  Herein we report the development and 
activity of a glucose-conjugated LDH-A inhibitor designed to target both of these 
tumor-promoting facets.   In addition to the promise of this conjugate, dual targeting 
of the Warburg effect using glycoconjugation as an anticancer strategy could be 
applied to inhibitors of many of the enzymes involved in glycolysis or tumor 
metabolism.   
 
